DiaMedica Therapeutics Inc. announced the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies. Prior to joining DiaMedica, Dr. Gruis served as Chief Medical Officer for Edgewise Therapeutics, Neuromuscular Franchise Head at Roche, Chief Medical Officer of Agilis Biotherapeutics Inc. and a number of additional senior clinical development roles at companies including Wave Life Sciences Ltd., Idera Pharmaceutics Inc., Alynylam Pharmaceuticals Inc. and Pfizer Inc. Prior to her time at Pfizer, Dr. Gruis was Associate Professor at SUNY Upstate and Assistant/Associate Professor at the University of Michigan, where she was a practicing neurologist for nearly ten years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | +8.44% |
|
+19.66% | +22.18% |
Jul. 01 | DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding | CI |
Jun. 27 | Transcript : DiaMedica Therapeutics Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.18% | 148M | |
+20.12% | 126B | |
+25.79% | 27.95B | |
-19.51% | 20.5B | |
-16.43% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B | |
+147.53% | 12.37B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. Appoints Kirsten Gruis as Chief Medical Officer